ZENTALIS PHARMACEUTICALS INC (ZNTL) Stock Fundamental Analysis

NASDAQ:ZNTL • US98943L1070

2.519 USD
+0.05 (+1.98%)
Last: Feb 25, 2026, 10:24 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ZNTL. ZNTL was compared to 521 industry peers in the Biotechnology industry. ZNTL has a great financial health rating, but its profitability evaluates not so good. ZNTL has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • ZNTL had negative earnings in the past year.
  • In the past year ZNTL has reported a negative cash flow from operations.
  • In the past 5 years ZNTL always reported negative net income.
  • In the past 5 years ZNTL always reported negative operating cash flow.
ZNTL Yearly Net Income VS EBIT VS OCF VS FCFZNTL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

  • ZNTL has a Return On Assets (-45.48%) which is in line with its industry peers.
  • With a decent Return On Equity value of -58.86%, ZNTL is doing good in the industry, outperforming 61.61% of the companies in the same industry.
Industry RankSector Rank
ROA -45.48%
ROE -58.86%
ROIC N/A
ROA(3y)-45.14%
ROA(5y)-40.51%
ROE(3y)-56.86%
ROE(5y)-50.48%
ROIC(3y)N/A
ROIC(5y)N/A
ZNTL Yearly ROA, ROE, ROICZNTL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

  • ZNTL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ZNTL Yearly Profit, Operating, Gross MarginsZNTL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -50K -100K -150K -200K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • ZNTL does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • ZNTL has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, ZNTL has more shares outstanding
  • ZNTL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ZNTL Yearly Shares OutstandingZNTL Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
ZNTL Yearly Total Debt VS Total AssetsZNTL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

  • Based on the Altman-Z score of -4.04, we must say that ZNTL is in the distress zone and has some risk of bankruptcy.
  • ZNTL has a Altman-Z score (-4.04) which is in line with its industry peers.
  • ZNTL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.04
ROIC/WACCN/A
WACC8.67%
ZNTL Yearly LT Debt VS Equity VS FCFZNTL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

  • A Current Ratio of 7.76 indicates that ZNTL has no problem at all paying its short term obligations.
  • With a decent Current ratio value of 7.76, ZNTL is doing good in the industry, outperforming 73.32% of the companies in the same industry.
  • A Quick Ratio of 7.76 indicates that ZNTL has no problem at all paying its short term obligations.
  • ZNTL's Quick ratio of 7.76 is fine compared to the rest of the industry. ZNTL outperforms 73.32% of its industry peers.
Industry RankSector Rank
Current Ratio 7.76
Quick Ratio 7.76
ZNTL Yearly Current Assets VS Current LiabilitesZNTL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 25.87% over the past year.
  • Looking at the last year, ZNTL shows a very negative growth in Revenue. The Revenue has decreased by -33.76% in the last year.
EPS 1Y (TTM)25.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.93%
Revenue 1Y (TTM)-33.76%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, ZNTL will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.91% on average per year.
  • ZNTL is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 31.87% yearly.
EPS Next Y11.5%
EPS Next 2Y7.94%
EPS Next 3Y8.44%
EPS Next 5Y11.91%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-32.89%
Revenue Next 5Y31.87%

3.3 Evolution

ZNTL Yearly Revenue VS EstimatesZNTL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2024 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M
ZNTL Yearly EPS VS EstimatesZNTL Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -2 -4

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • ZNTL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ZNTL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ZNTL Price Earnings VS Forward Price EarningsZNTL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ZNTL Per share dataZNTL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.94%
EPS Next 3Y8.44%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for ZNTL!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ZENTALIS PHARMACEUTICALS INC

NASDAQ:ZNTL (2/25/2026, 10:24:03 AM)

2.519

+0.05 (+1.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10
Earnings (Next)03-24
Inst Owners62.02%
Inst Owner Change-22.23%
Ins Owners12.12%
Ins Owner Change-0.27%
Market Cap182.00M
Revenue(TTM)26.86M
Net Income(TTM)-148.84M
Analysts77.33
Price Target4.9 (94.52%)
Short Float %7.23%
Short Ratio2.71
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)34.44%
Min EPS beat(2)31.28%
Max EPS beat(2)37.6%
EPS beat(4)4
Avg EPS beat(4)24.17%
Min EPS beat(4)13.88%
Max EPS beat(4)37.6%
EPS beat(8)7
Avg EPS beat(8)26.27%
EPS beat(12)9
Avg EPS beat(12)13.53%
EPS beat(16)11
Avg EPS beat(16)12.04%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-9.65%
PT rev (3m)-9.65%
EPS NQ rev (1m)-35.71%
EPS NQ rev (3m)-7.53%
EPS NY rev (1m)-8.48%
EPS NY rev (3m)8.47%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.77
P/FCF N/A
P/OCF N/A
P/B 0.72
P/tB 0.72
EV/EBITDA N/A
EPS(TTM)-1.92
EYN/A
EPS(NY)-1.9
Fwd EYN/A
FCF(TTM)-1.86
FCFYN/A
OCF(TTM)-1.86
OCFYN/A
SpS0.37
BVpS3.5
TBVpS3.5
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -45.48%
ROE -58.86%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-45.14%
ROA(5y)-40.51%
ROE(3y)-56.86%
ROE(5y)-50.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.76
Quick Ratio 7.76
Altman-Z -4.04
F-Score3
WACC8.67%
ROIC/WACCN/A
Cap/Depr(3y)79.15%
Cap/Depr(5y)368.78%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.93%
EPS Next Y11.5%
EPS Next 2Y7.94%
EPS Next 3Y8.44%
EPS Next 5Y11.91%
Revenue 1Y (TTM)-33.76%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-32.89%
Revenue Next 5Y31.87%
EBIT growth 1Y26.82%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year27.07%
EBIT Next 3Y8.71%
EBIT Next 5YN/A
FCF growth 1Y34.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y34.34%
OCF growth 3YN/A
OCF growth 5YN/A

ZENTALIS PHARMACEUTICALS INC / ZNTL FAQ

What is the ChartMill fundamental rating of ZENTALIS PHARMACEUTICALS INC (ZNTL) stock?

ChartMill assigns a fundamental rating of 3 / 10 to ZNTL.


What is the valuation status of ZENTALIS PHARMACEUTICALS INC (ZNTL) stock?

ChartMill assigns a valuation rating of 0 / 10 to ZENTALIS PHARMACEUTICALS INC (ZNTL). This can be considered as Overvalued.


Can you provide the profitability details for ZENTALIS PHARMACEUTICALS INC?

ZENTALIS PHARMACEUTICALS INC (ZNTL) has a profitability rating of 1 / 10.


What is the earnings growth outlook for ZENTALIS PHARMACEUTICALS INC?

The Earnings per Share (EPS) of ZENTALIS PHARMACEUTICALS INC (ZNTL) is expected to grow by 11.5% in the next year.